| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5696971 | Brachytherapy | 2017 | 7 Pages |
Abstract
Hypofractionation up to a single-fraction HDR-BT boost for prostate cancer yields similar results in terms of biochemical control and late toxicity compared with two or three-fraction schemes. Single fraction HDR-BT appears acceptable for boosting prostate cancer after definitive EBRT.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Alexander T. Falk, Sylvain Demontoy, Emmanuel Chamorey, Marie-Eve Chand, Mathieu Gautier, David Azria, Sara Zaki, Daniel Chevallier, Daniel Lam Cham Kee, Jean-Michel Hannoun-Lévi,